Early Detection of Cardiac Damage With CMR in Women With Breast Cancer
NCT ID: NCT04046315
Last Updated: 2020-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
55 participants
OBSERVATIONAL
2020-03-01
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Detection of Imaging-derived Subclinical Cardiac Injuries
NCT03575650
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
NCT04790266
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping
NCT03940625
MyoStrain CMR for the Detection of Cardiotoxicity
NCT03543228
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
NCT05851053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CMR
GLS measurement with CMR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years
* A diagnosis of primary breast cancer
* Starting (neo-) adjuvant chemotherapy treatment within 2 months after screening
* Cardiotoxicity risk score of intermediate, high or very high risk
Exclusion Criteria
* Cancer metastasis
* Life expectancy of less than 6 months
* History of myocardial infarction or heart failure
* Known contra-indications for CMR
* Refusal or inability to provide informed consent
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Saloua El Messaoudi, PhD
Role: STUDY_CHAIR
Radboud University Medical Center
Angela Maas, PhD
Role: PRINCIPAL_INVESTIGATOR
Radboud University Medical Center
Robin Nijveldt, PhD
Role: STUDY_CHAIR
Radboud University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radboud University Medical Center
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yvonne Koop, MSc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
108818
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.